Chlamydia trachomatis is responsible for the most frequent sexually transmitted bacterial infection in the world and for trachoma, the world's leading infectious cause of blindness. Genital chlamydial infection is very common among sexually active young people, and when untreated, leads to serious complications. No vaccine is yet available for this bacterial infection. Although Chlamydia resistance to antibiotics is rarely observed in vivo, studies showed that 10-20% of patients remain infected at the end of antibiotherapy, without being reinfected. The present review gives a global and comprehensive overview of the different targets and the related inhibitors proposed during the last dec-ade, with a view to limiting the growth of this human pathogen. Metallic and polymeric nanoparticles in this field are also briefly presented.
Bibliographical noteFunding Information:
This work was supported by a Ph.D. grant from the University of Science and Technology of Hanoi (Vu T.H.). The Institut des Humanités de Paris (Paris Diderot), the National Center for Scientific Research (CNRS) and the University Paris Diderot are gratefully thanked for financial support. The authors also thank John S. Lomas for carefully reading the manuscript.
© 2018 Bentham Science Publishers.
- Chlamydia trachomatis
- Gram-negative bacteria